{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29",
    "query": {
      "intervention": "Glucagon-Like Peptide-1 Agonist (GLP-1)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 177,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T17:35:14.385Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07220473",
      "title": "Tirzepatide to Slow Biological Aging",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aging",
        "LONGEVITY 1"
      ],
      "interventions": [
        {
          "name": "Zepbound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "55 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-02-27",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220473"
    },
    {
      "nct_id": "NCT07744360",
      "title": "A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "GI Symptoms"
      ],
      "interventions": [
        {
          "name": "Prebiotic Soda",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Olipop, PBC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-02-10",
      "completion_date": "2026-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07744360"
    },
    {
      "nct_id": "NCT07756359",
      "title": "Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pouch, Ileal",
        "Pouches, Ileoanal",
        "Bowel Diseases, Inflammatory"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Loperamide",
          "type": "DRUG"
        },
        {
          "name": "Diphenoxylate/Atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756359"
    },
    {
      "nct_id": "NCT01524705",
      "title": "FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Prandial insulin",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2012-08",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524705"
    },
    {
      "nct_id": "NCT06005012",
      "title": "Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrosis, Liver",
        "Type 2 Diabetes Mellitus in Obese",
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 120,
      "start_date": "2023-07-25",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005012"
    },
    {
      "nct_id": "NCT07115069",
      "title": "Comparison of Body Composition Changes With Weight Loss Interventions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Gastric Bypass Surgery (laparoscopic)",
          "type": "PROCEDURE"
        },
        {
          "name": "Gastric Bypass Surgery (robotic)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-08-09",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07115069"
    },
    {
      "nct_id": "NCT05390892",
      "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type2Diabetes",
        "ASCVD"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 6000,
      "start_date": "2022-09-26",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 36,
      "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05390892"
    },
    {
      "nct_id": "NCT06410924",
      "title": "A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NAFLD",
        "NASH"
      ],
      "interventions": [
        {
          "name": "DD01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neuraly, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 67,
      "start_date": "2024-06-13",
      "completion_date": "2026-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 12,
      "location_summary": "Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Monroe",
          "state": "Louisiana"
        },
        {
          "city": "West Monroe",
          "state": "Louisiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06410924"
    },
    {
      "nct_id": "NCT05214573",
      "title": "Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes",
        "Cardiac Disease"
      ],
      "interventions": [
        {
          "name": "Glucagon like peptide 1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Sodium-glucose cotransporter 2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase 4 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 386301,
      "start_date": "2021-12-01",
      "completion_date": "2025-07-22",
      "has_results": true,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05214573"
    },
    {
      "nct_id": "NCT06069622",
      "title": "Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "24-hour ambulatory blood pressure",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Liberal salt diet",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-07T17:35:14.385Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06069622"
    }
  ]
}